Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system-Reference-Cited by-同舟云学术

Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system

Published:2023-01-01 Issue:1 Volume:5 Page:
ISSN:2632-2498
Container-title:Neuro-Oncology Advances
language:en
Short-container-title:

Author:

Renovanz Mirjam¹²³,Kurz Sylvia C¹²,Rieger Johannes¹²,Walter Bianca¹,Becker Hannes¹²³,Hille Hanni¹,Bombach Paula¹²⁴,Rieger David¹²,Grosse Lucia¹²,Häusser Lara¹⁵,Skardelly Marco¹²,Merk Daniel J¹,Paulsen Frank²⁴⁶,Hoffmann Elgin²⁴⁶,Gani Cihan²⁴⁶⁵,Neumann Manuela²⁴⁷⁵,Beschorner Rudi²⁴⁷⁵,Rieß Olaf⁴⁸⁹⁵,Roggia Cristiana⁴⁸,Schroeder Christopher⁴⁸,Ossowski Stephan⁴⁸,Armeanu-Ebinger Sorin⁴⁸,Gschwind Axel⁴⁸,Biskup Saskia¹⁰⁹,Schulze Martin¹⁰,Fend Falko⁴¹¹⁹⁵^ORCID,Singer Stephan⁴¹¹⁹⁵,Zender Lars⁴¹²⁹⁵,Lengerke Claudia¹³⁵,Brucker Sara Yvonne¹⁴⁵^ORCID,Engler Tobias¹⁴⁵,Forschner Andrea¹⁵⁵,Stenzl Arnulf¹⁶⁵,Kohlbacher Oliver⁴¹⁷⁵^ORCID,Nahnsen Sven⁴¹⁸¹²⁹⁵^ORCID,Gabernet Gisela¹⁸,Fillinger Sven¹⁸,Bender Benjamin²⁴¹⁹,Ernemann Ulrike²⁴¹⁹,Öner Öznur⁴,Beha Janina⁴,Malek Holly Sundberg⁴,Möller Yvonne⁴,Ruhm Kristina⁴,Tatagiba Marcos²⁴³,Schittenhelm Jens²⁴⁷⁵^ORCID,Bitzer Michael⁴²⁰⁹⁵,Malek Nisar⁴²⁰⁹⁵,Zips Daniel²⁴⁶⁵,Tabatabai Ghazaleh¹²⁴⁹⁵^ORCID

Affiliation:

1. Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen , Germany

2. Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen , Germany

3. Department of Neurosurgery, Eberhard Karls University Tübingen , Germany

4. Center for Personalized Medicine Tübingen, Eberhard Karls University Tübingen , Germany

5. German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Eberhard Karls University of Tübingen , Germany

6. Department of Radiation Oncology, Eberhard Karls University Tübingen , Germany

7. Institute of Pathology and Neuropathology, Department of Neuropathology, Eberhard Karls University Tübingen , Germany

8. Institute of Medical Genetics and Applied Genomics, Eberhard Karls University Tübingen , Germany

9. Cluster of Excellence (EXC 2180) “Image Guided and Functionally Instructed Tumor Therapies“, Eberhard Karls University of Tübingen , Germany

10. Center for Genomics and Transcriptomics (CeGaT) & Center for Human Genetics Tübingen , Germany

11. Department of Pathology and Neuropathology, Institute of Pathology and Molecular Pathology, Eberhard Karls University Tübingen , Germany

12. Department of Medical Oncology and Pneumology (Internal Medicine VIII), Eberhard Karls University Tübingen , Germany

13. Department of Internal Medicine II, Eberhard Karls University Tübingen , Germany

14. Department of Gynecology and Obstetrics, Eberhard Karls University Tübingen , Germany

15. Department of Dermatology and Center for Dermato-Oncology, Eberhard Karls University Tübingen , Germany

16. Department of Urology, Eberhard Karls University Tübingen , Germany

17. Institute for Translational Bioinformatics, Eberhard Karls University Tübingen , Germany

18. Quantitative Biology Center (QBiC), Eberhard Karls University Tübingen , Germany

19. Department of Diagnostic and Interventional Neuroradiology, Department of Radiology, Eberhard Karls University Tübingen , Germany

20. Department of Internal Medicine I, Eberhard Karls University Tübingen , Germany

Abstract

AbstractBackgroundThe clinical utility of molecular profiling and targeted therapies for neuro-oncology patients outside of clinical trials is not established. We aimed at investigating feasibility and clinical utility of molecular profiling and targeted therapy in adult patients with advanced tumors in the nervous system within a prospective observational study.Methodsmolecular tumor board (MTB)@ZPM (NCT03503149) is a prospective observational precision medicine study for patients with advanced tumors. After inclusion of patients, we performed comprehensive molecular profiling, formulated ranked biomarker-guided therapy recommendations based on consensus by the MTB, and collected prospective clinical outcome data.ResultsHere, we present initial data of 661 adult patients with tumors of the nervous system enrolled by December 31, 2021. Of these, 408 patients were presented at the MTB. Molecular-instructed therapy recommendations could be made in 380/408 (93.1%) cases and were prioritized by evidence levels. Therapies were initiated in 86/380 (22.6%) cases until data cutoff. We observed a progression-free survival ratio >1.3 in 31.3% of patients.ConclusionsOur study supports the clinical utility of biomarker-guided therapies for neuro-oncology patients and indicates clinical benefit in a subset of patients. Our data might inform future clinical trials, translational studies, and even clinical care.

Funder

German Scholars Organization

Else Kröner Forschungskolleg Tübingen

Medical Faculty Tübingen

Publisher

Oxford University Press (OUP)

Subject

Surgery,Oncology,Neurology (clinical)

Link

https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdad012/49177304/vdad012.pdf

Reference36 articles.

1. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study;Hainsworth;J Clin Oncol,2018